Unknown

Dataset Information

0

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.


ABSTRACT: Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy. Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term persistence. Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.The basic structure of so-called first and later generation CARs and their potential advantages over other immune therapy systems. How these molecules can be grafted into immune cells (including retroviral and non-retroviral transduction methods) and strategies to improve the in vivo persistence and function of immune cells expressing CARs. Examples of tumor-associated antigens that have been targeted in preclinical models and clinical experience with these modified cells. Safety issues surrounding CAR gene transfer into T cells and potential solutions to them.Because of recent advances in immunology, genetics and cell processing, CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic infections and autoimmune disorders.

SUBMITTER: Ramos CA 

PROVIDER: S-EPMC3107373 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Ramos Carlos A CA   Dotti Gianpietro G  

Expert opinion on biological therapy 20110404 7


<h4>Introduction</h4>Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy. Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential benefits of active trafficking to tumor sit  ...[more]

Similar Datasets

| S-EPMC10413722 | biostudies-literature
| S-EPMC5532628 | biostudies-literature
| S-EPMC9509604 | biostudies-literature
| S-EPMC8930424 | biostudies-literature
| S-EPMC5738277 | biostudies-literature
| S-EPMC7140022 | biostudies-literature
| S-EPMC8343118 | biostudies-literature
| S-EPMC8583883 | biostudies-literature
| S-EPMC10327905 | biostudies-literature
| S-EPMC4448187 | biostudies-literature